Sacubitril/Valsartan vs ACE Inhibitors or ARBs
The SAV-treated group, across all EF spectrum, was less likely to be rehospitalized than the ACEI/ARB-treated group. However, all-cause mortality reduction was only noted in the SAV group with EF <40%. No reduction in CV-related mortality was observed across the EF spectrum.
Authors
- Abiodun Idowu (ORCID: https://orcid.org/0000-0003-4702-9233)
- Shane LaRue (ORCID: https://orcid.org/0000-0003-1048-649X)
- Endurance O Evbayekha (ORCID: https://orcid.org/0000-0002-1060-1921)
Institutions
- Jefferson Einstein Philadelphia Hospital (US)
- St. Luke's Hospital (US)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1016/j.jacadv.2025.101598
- Citations
- 5
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.94